Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Project Summary: Annually, millions of patients are diagnosed with autoimmune disorders. The majority of these are treated with global immune suppressants. These drugs often tip the balance from autoimmunity to immune suppression, triggering undesirable, systemic side effects. Previously, it had been established in literature that Exportin-1 (XPO1) is a novel target for the inhibition of T cell activation. XPO1 is canonically recognized as a nuclear cargo export protein where it shuttles cargo from the nucleus into the cytoplasm. Recently, it has been reported that XPO1 also plays a critical role as a chromatin factor. XPO1’s chromatin function can be inhibited with novel molecules coined “Selective Inhibitors of Transcriptional Activation” (SITAs). Mechanistically, it has been determined that these SITAs covalently bind to the C528 position of XPO1 in the same binding pocket as known nuclear export inhibitors called “Selective Inhibitors of Nuclear Export” (SINEs), as exemplified by the FDA approved inhibitor, Selinexor. While SITAs and SINEs covalently engage the same pocket, it is mechanistically unclear how and why these reported SITAs have the disparate phenotypic effect of inhibiting T cell activation compared to established SINEs which inhibit nuclear export. This proposal seeks to test the central hypothesis that the SITAs’ phenotypic deviation from SINEs stems from the rapid reversion of the covalent bond formed by SITAs in the C528 pocket.
Grant Summary
Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $55K for university, nonprofit, healthcare org. Applications are due 2030-05-25 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $55K
2030-05-25
- 1Confirm your organization is eligible for Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation: Frequently Asked Questions
Who is eligible for the Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation?
Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation provide?
Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation provides up to $55K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation deadline?
Applications for Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation are due 2030-05-25 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation?
To apply for Characterizing Selective Inhibitors of Transcriptional Activity as Therapeutics for Pathological T Cell Activation, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.